post huge top bottom beat driven record new patient add
guidanc withdrawn howev strength commentari april new patient add
support upward estim revis delay month ideal thesi
chang continu best product pipelin vast under-penetrated
remain top pick p-t
revenu y/i exceed expect strength
broad base across geographi intern sale y/i cc new patient
addit primari driver upsid repres record quarter despit
typic season weaker estim new patient add approach
forecast
gross margin y/i came consensu oper margin
y/i came forecast strong top bottom upsid
result ep consensu
guidanc suspend howev manag commentari suggest april
new patient addit better fear less alreadi
improv increas beyond forecast meaning account
strength april commentari ultim continu see clear room upsid
vs revis forecast top bottom line
manag expect delay minimum month due clinic trial delay
endocrinologist offic current close manag stress uncertainti
time reopen patient willing particip clinic trial
requir signific time clinic patient huge catalyst stock
busi delay ideal particularli libr end launch sooner
investor current expect howev expect materi impact competit
post anoth blow-out quarter impress new patient momentum suggest
upsid come thesi remain unchang best product pipelin
softwar vast under-penetrated expect continu upward
estim revis cours also believ non-intens type progress
margin trajectori remain underappreci investor remain
top pick increas price target dcf sale
pleas see page report import disclosur
believ make core growth stori attract
market dynam technolog differenti top-tier manag team
scalabl profit model longer term price headwind exist howev non-
intens type adopt come fruition believ question volume/
revenue/profit upsid like signific even modest downsid price scenario
occur best product pipelin industri expect remain clear
cgm market leader forese futur wherev market goe top
non-intens updat key partner
type cgm penetr continu
rapidli increas toward standard
care ou remain significantli
inflect
limit non-intens revenu
annual next year
revenu growth sustain pace
beyond
faster expect payer
signific gross margin upsid
scale
price declin faster
competitor close gap accuracy/
reliabl faster expect
found headquart san diego california medic devic
compani focus design develop commerci continu glucos
monitor cgm system use peopl diabet flagship offer today
dexcom system patient diabet detect trend track glucos
pattern move forward compani focus continu drive advanc
cgm technolog focus accuraci comfort connect longer term
goal drive cgm adopt across entir spectrum diabet care
compani report thomson eikon cowen compani
cowen vs consensu mm except non-gaap revenu metric mm except statement mm except per count ep came revenu came expect upsid driven robust exist patient util well much better expect new patient add strength broad base across geographi commerci channel sensor util strong impress quarter non-gaap gross margin came expect consensu expens forecast though sale sg forecast though oper margin durabl revenu beat forecast strength seemingli driven recur revenu transmitt util much better expect new patient add record quarter new patient add estim nearli sensor revenu expect better expect result seemingli driven new patient upsid strong exist patient util like degre stock clearli cowen
compani report thomson eikon cowen compani
mm except per share guidanc suspend day profit guidanc suspend day gener oper guidanc suspend non-gaap day zero per manag still day less long termnet earn per consensu estim mm except per share gross op cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
risk includ limit cgm penetr fail increas competit product
reduc competit moat profit push back materi new product
releas delay due regulatori hurdl trade signific premium
